AZN vs SABA
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AZN is a StrongBuy and SABA is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AZN’s FA Score shows that 2 FA rating(s) are green while.
- AZN’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AZN’s TA Score shows that 4 TA indicator(s) are bullish.
- AZN’s TA Score: 4 bullish, 6 bearish.
Price Growth
AZN (@Pharmaceuticals: Major) experienced а -2.02% price change this weekfor the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.44%. For the same industry, the average monthly price growth was +7.21%, and the average quarterly price growth was -5.03%.
Reported Earning Dates
AZN is expected to report earnings on Jul 24, 2025.
Industries' Descriptions
@Pharmaceuticals: Major (-0.44% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
AZN | ||
|---|---|---|
OUTLOOK RATING 1..100 | 15 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 26 Undervalued | |
PROFIT vs RISK RATING 1..100 | 30 | |
SMR RATING 1..100 | 50 | |
PRICE GROWTH RATING 1..100 | 47 | |
P/E GROWTH RATING 1..100 | 74 | |
SEASONALITY SCORE 1..100 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| AZN | SABA | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 44% | 2 days ago 80% |
| Stochastic ODDS (%) | 2 days ago 48% | 2 days ago 72% |
| Momentum ODDS (%) | 2 days ago 64% | 2 days ago 83% |
| MACD ODDS (%) | 2 days ago 64% | 2 days ago 78% |
| TrendWeek ODDS (%) | 2 days ago 46% | 2 days ago 74% |
| TrendMonth ODDS (%) | 2 days ago 44% | 2 days ago 77% |
| Advances ODDS (%) | 8 days ago 54% | 8 days ago 76% |
| Declines ODDS (%) | 2 days ago 45% | 2 days ago 74% |
| BollingerBands ODDS (%) | 2 days ago 43% | 2 days ago 67% |
| Aroon ODDS (%) | 2 days ago 55% | 2 days ago 76% |
SABA and
Correlation & Price change
A.I.dvisor tells us that SABA and JPM have been poorly correlated (+7% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SABA and JPM's prices will move in lockstep.
| Ticker / NAME | Correlation To SABA | 1D Price Change % | ||
|---|---|---|---|---|
| SABA | 100% | -0.57% | ||
| JPM - SABA | 7% Poorly correlated | -1.31% | ||
| AZN - SABA | 5% Poorly correlated | -2.54% |